JP2007528866A - 駆虫組成物 - Google Patents
駆虫組成物 Download PDFInfo
- Publication number
- JP2007528866A JP2007528866A JP2006519991A JP2006519991A JP2007528866A JP 2007528866 A JP2007528866 A JP 2007528866A JP 2006519991 A JP2006519991 A JP 2006519991A JP 2006519991 A JP2006519991 A JP 2006519991A JP 2007528866 A JP2007528866 A JP 2007528866A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- closantel
- delivery system
- group
- ivermectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 88
- 230000000507 anthelmentic effect Effects 0.000 title description 8
- JMPFSEBWVLAJKM-UHFFFAOYSA-N N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide Chemical compound ClC=1C=C(NC(=O)C=2C(=C(I)C=C(I)C=2)O)C(C)=CC=1C(C#N)C1=CC=C(Cl)C=C1 JMPFSEBWVLAJKM-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229950004178 closantel Drugs 0.000 claims abstract description 41
- 239000004540 pour-on Substances 0.000 claims abstract description 24
- -1 closantel Chemical compound 0.000 claims abstract description 21
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 19
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 16
- 239000005660 Abamectin Substances 0.000 claims abstract description 15
- WKEDVNSFRWHDNR-UHFFFAOYSA-N salicylanilide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=CC=C1 WKEDVNSFRWHDNR-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229950000975 salicylanilide Drugs 0.000 claims abstract description 13
- 150000001298 alcohols Chemical class 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 239000003096 antiparasitic agent Substances 0.000 claims abstract description 10
- 230000002141 anti-parasite Effects 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 229920001983 poloxamer Polymers 0.000 claims abstract description 8
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims abstract description 7
- 238000009472 formulation Methods 0.000 claims description 49
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 31
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 31
- 229960002418 ivermectin Drugs 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 241000242541 Trematoda Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 230000035515 penetration Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 235000019658 bitter taste Nutrition 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 150000002191 fatty alcohols Chemical group 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 244000045947 parasite Species 0.000 abstract description 18
- 230000036470 plasma concentration Effects 0.000 abstract description 18
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 abstract description 15
- 241001465754 Metazoa Species 0.000 abstract description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract description 4
- 229920001400 block copolymer Polymers 0.000 abstract description 4
- 230000000699 topical effect Effects 0.000 abstract description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 abstract 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 239000002904 solvent Substances 0.000 description 14
- 229940124339 anthelmintic agent Drugs 0.000 description 12
- 239000000921 anthelmintic agent Substances 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 244000078703 ectoparasite Species 0.000 description 5
- 229960000502 poloxamer Drugs 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 244000079386 endoparasite Species 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000935974 Paralichthys dentatus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229920001451 polypropylene glycol Polymers 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BHFLSZOGGDDWQM-UHFFFAOYSA-N 1h-benzimidazole;carbamic acid Chemical class NC(O)=O.C1=CC=C2NC=NC2=C1 BHFLSZOGGDDWQM-UHFFFAOYSA-N 0.000 description 1
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical class C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241001468227 Streptomyces avermitilis Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000002635 aromatic organic solvent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000008331 benzenesulfonamides Chemical class 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- VEMKTZHHVJILDY-UXHICEINSA-N bioresmethrin Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OCC1=COC(CC=2C=CC=CC=2)=C1 VEMKTZHHVJILDY-UXHICEINSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000000047 flukicidal effect Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229940074076 glycerol formal Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- FSVSNKCOMJVGLM-UHFFFAOYSA-N octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O FSVSNKCOMJVGLM-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960000323 triclabendazole Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/36—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids
- A01N37/38—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system
- A01N37/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a singly bound oxygen or sulfur atom attached to the same carbon skeleton, this oxygen or sulfur atom not being a member of a carboxylic group or of a thio analogue, or of a derivative thereof, e.g. hydroxy-carboxylic acids having at least one oxygen or sulfur atom attached to an aromatic ring system having at least one carboxylic group or a thio analogue, or a derivative thereof, and one oxygen or sulfur atom attached to the same aromatic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/609—Amides, e.g. salicylamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pest Control & Pesticides (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Road Paving Structures (AREA)
- Toxicology (AREA)
Abstract
Description
本発明は、駆虫組成物に関し、特に、随意に他の駆虫剤、例えば、アベルメクチン(avermectin)またはミルベマイシン(milbemycin)とともにサリチルアニリドに基づく、獣医用配合剤(combination products)に関する。かかる配合剤は、単体の駆虫剤の単独での使用によって確認されるよりも広いスペクトラムの寄生虫に亘る有効性を示す。
温血動物は寄生虫の攻撃にさらされており、人は、家庭内のペット、飼育された家畜および外来動物を苦しめるこのような寄生虫の対策、苦痛の緩和および商売上の利益のために、長く模索してきた。寄生虫による攻撃方法および寄生虫の生活環における感受性ステージの同定は、防除剤の選択に大きく影響を与え得る。したがって、ローション剤、ペイント剤、クリーム剤、ゲル剤、粉剤、「ポアオン剤(pour-on)」およびディップ剤などの局所的に塗布する製剤を用いた経皮的処置は外部寄生虫に対して共通して好適であるが、しかし、内部寄生虫を防除するためには、投与方法および送達システムの注意深い選択が要求される。
伝統的な駆虫剤には、ベンズイミダゾールなどの化学剤およびカーバメートならびにマダニ(ticks)およびハダニ(mites)などの外部寄生虫に対抗するために用いられる傾向にあるピレスロイドなどの植物抽出物が含まれる。
したがって、現在、ポアオン剤としてクロサンテルの投与に適合した既知の市販の処方はない。
イベルメクチンは、殺虫組成物における特に好ましい活性成分であり、その活性についての豊富な文献があり、その内部および外部の寄生虫に対する有効性およびある寄生虫の生活環に干渉する能力が示されている。The Merck Index (1996) には、わずかであるが、J.C.Chabala et al, J.Med.Chem.23, 1134 (1980); J.R.Egerton et al, Brit.Vet.J.136, 88 (1980); W.C.Campbell et al, Science 221, 823-828 (1983)を含むいくつかの参考文献が挙げられている。
したがって、本発明の課題は、改善された獣医用医薬製剤を提供することである。特に本発明の課題は、吸虫類を含む広い範囲の内部および外部寄生虫に対して活性を有する組成物を提供することである。本発明のさらなる課題は、好ましくはポアオン処方としてクロサンテルが存在する、局所投与に好適な製剤を提供することである。本発明のまたさらなる課題は、先行技術において既知のものを超えてクロサンテルの生体利用性を増大させることが可能な効果的な処方の、イベルメクチンおよびクロサンテルを配合した獣医薬製品を提供することである。
驚くべきことに、サリチルアニリドは、随意に他の寄生虫駆除剤と共に、1種または2種以上のアルコール類に溶解することができ、およびこの処方は、予め決定された期間にわたり動物の皮膚に局所適用するとき、動物の血中で有効なレベルのサリチルアニリドならびに他の寄生虫駆除剤を提供する「ポアオン剤」処方として有用であることが見出された。
PEGなどのポリマー成分の存在により、本発明のポアオン処方に溶解可能なクロサンテルのレベルが増加すると考えられる。
したがって、本発明によれば、サリチルアニリド、好ましくはクロサンテルと、アベルメクチン、好ましくはイベルメクチンとの単一の注射可能な処方を得ることが可能であり、動物に投与した場合、クロサンテルおよびイベルメクチンの効果的な血漿濃度が容易に達成できるように効果的にクロサンテルを送達する。もちろん、臨床的理由により、所望の場合、これらの活性成分の1種のみを含有する処方を利用することができる。
クロサンテル − 1〜30%w/v、好ましくは1〜15%w/v;
イベルメクチン − 0.1〜10%w/v、好ましくは0.1〜5%w/v;
である。
効果的であることが要求されるポリマー成分、特にPEGの量は、混合物の所望のサリチルアニリド活性に依存するが、好ましくは少なくとも3%(w/v)のPEG、より好ましくは20%(w/v)が、例えば、達成が望まれるクロサンテルのより高い効果的な量を可能にするために使用される。使用されるポリマー材料の量は、送達システムにおいて使用されるアルコールの量のみに限定され、したがって80%v/vまでであり得る。
以下の一枚の添付図面は、本発明の処方と市販品との薬物動態プロファイルの比較をグラフにより説明する。
本発明を、現在知られている最良の形態に従って具体例により、さらに説明する。
ポアオンプレゼンテーションにおける送達のための2成分配合剤の調製において、活性成分クロサンテルおよびイベルメクチンについて、10%(w/v)のクロサンテルおよび0.5%(w/v)のイベルメクチンを送達するための量を提供した。使用した送達システムは、活性物の効果的な溶媒化のために容易に提供される溶媒PEG200、エタノールおよびイソプロピルアルコールを、透過促進剤とともに含み、いくつかの具体的な処方の組成物は、以下のとおりである:
これらの処方は、通常の工業的手法に続いて仕上げた。
上記のように作成した処方(1、2および3)を、認められた工業的手順に従い、投与のために提示し、それらの試験を以下に示す。
上記組成物(処方1、2および3)に従った、クロサンテルおよびイベルメクチン含有の処方を、500μg/kg体重に等しいイベルメクチン用量率、および10mg/kg体重のクロサンテル用量率でウシに適用した。
クロサンテルについての血漿結果を、表1、4および5に、およびイベルメクチンについてを、表2、3および6に示す。
本明細書に記載の構成の先に述べた利点および特性の観点から、本発明は、特に、典型的に、ウシ、ウマ、ヒツジおよびヤギなどの家畜を苦しめる内部寄生虫および外部寄生虫に対抗するため、獣医薬の分野において有用に適用される。
Claims (19)
- 抗寄生虫ポアオン組成物であり、少なくとも20%(v/v)の1種または2種以上のアルコール類を含む送達システム、および有効量のサリチルアニリド抗寄生虫化合物の存在により特徴付けられる、前記組成物。
- さらに有効量の少なくとも1種の他の抗寄生虫化合物を含む、請求項1に記載の抗寄生虫組成物。
- サリチルアニリドがクロサンテルまたはその薬学的に許容しうる塩である、請求項1に記載の組成物。
- 他の抗寄生虫化合物が、ミルベマイシンからなる群から選択される、請求項2または3に記載の組成物。
- 他の抗寄生虫化合物は、アベルメクチンからなる群から選択される、請求項2に記載の組成物。
- 抗寄生虫化合物はイベルメクチンである、請求項5に記載の組成物。
- イベルメクチンが、0.1〜10%(w/v)の範囲の量で存在する、請求項6に記載の組成物。
- クロサンテルが、1〜30%(w/v)の量で存在する、請求項2または3に記載の組成物。
- 送達システムが、第一級、第二級、および第三級脂肪族アルコール類からなる群から選択されるアルコール類を含む、請求項1に記載の組成物。
- 送達システムが、芳香族アルコール類からなる群から選択されるアルコール類を含む、請求項1に記載の組成物。
- 送達システムが、低級アルカノール類(C1〜C6)からなる群から選択されるアルコール類を含む、請求項1に記載の組成物。
- 送達システムが、ポリエチレングリコール、イソプロピルアルコールおよび少なくとも20%のエタノールを含む、請求項1に記載の組成物。
- 送達システムが、ポリエチレングリコール、ポリビニルピロリドンおよびポロクサマー類からなる群から選択される1種または2種以上のポリマー成分を含む、請求項1に記載の組成物。
- ポリマー成分が、0.1%(w/v)〜80%(w/v)の範囲の量で存在する、請求項13に記載の組成物。
- ポリマー成分が、3%(w/v)〜20%(w/v)の範囲の量で存在する、請求項13に記載の組成物。
- ポリマー成分がポリビニルピロリドンである、請求項13に記載の組成物。
- 送達システムがまた、以下の助剤:界面活性剤、苦味変性剤(舐め防止剤)、保存剤、拡散助剤、浸透または閉塞促進剤、および抗酸化剤、の少なくとも1種を含む、請求項1に記載の組成物。
- 成虫の吸虫類および未成熟の吸虫類を根絶することにおける使用のための、請求項1に記載の組成物。
- 本明細書中の処方例に記載の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0316377.1A GB0316377D0 (en) | 2003-07-12 | 2003-07-12 | Parasiticidal composition |
PCT/GB2004/003006 WO2005007241A1 (en) | 2003-07-12 | 2004-07-12 | Parasiticidal composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007528866A true JP2007528866A (ja) | 2007-10-18 |
JP4677405B2 JP4677405B2 (ja) | 2011-04-27 |
Family
ID=27742085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006519991A Active JP4677405B2 (ja) | 2003-07-12 | 2004-07-12 | 駆虫組成物 |
Country Status (29)
Country | Link |
---|---|
US (1) | US8993546B2 (ja) |
EP (2) | EP1646425B1 (ja) |
JP (1) | JP4677405B2 (ja) |
KR (1) | KR101095419B1 (ja) |
CN (1) | CN1822880B (ja) |
AP (1) | AP2956A (ja) |
AU (1) | AU2004257450B2 (ja) |
BR (1) | BRPI0412522A (ja) |
CA (1) | CA2532199C (ja) |
CR (1) | CR8174A (ja) |
DK (1) | DK1646425T3 (ja) |
EA (1) | EA009602B1 (ja) |
EC (1) | ECSP066360A (ja) |
ES (1) | ES2390224T3 (ja) |
GB (2) | GB0316377D0 (ja) |
GE (1) | GEP20094648B (ja) |
HK (1) | HK1096621A1 (ja) |
HR (1) | HRP20120721T1 (ja) |
IL (1) | IL173057A (ja) |
MX (1) | MXPA06000135A (ja) |
NO (1) | NO336181B1 (ja) |
NZ (1) | NZ544973A (ja) |
OA (1) | OA13188A (ja) |
PL (1) | PL1646425T3 (ja) |
PT (1) | PT1646425E (ja) |
SI (1) | SI1646425T1 (ja) |
TN (1) | TNSN06006A1 (ja) |
WO (1) | WO2005007241A1 (ja) |
ZA (1) | ZA200600374B (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
GB0501220D0 (en) * | 2005-01-21 | 2005-03-02 | Norbrook Lab Ltd | Anthelmintic composition |
GB0711957D0 (en) * | 2007-06-21 | 2007-08-01 | Syntopix Ltd | Formulations |
CN101693009B (zh) * | 2009-10-27 | 2010-12-01 | 纽素乐必佳(天津)药业集团有限公司 | 牛羊用抗寄生虫病氯氰碘柳胺钠透皮溶液及其制备方法 |
FR2991173B1 (fr) | 2012-06-04 | 2015-11-06 | Virbac | Composition veterinaire a administration cutanee a base d'oxyclozanide |
CN103720652B (zh) * | 2014-01-07 | 2016-09-28 | 王玉万 | 用泊洛沙姆和油性介质制备含阿维菌素类药物注射剂 |
WO2019054967A2 (en) * | 2017-03-15 | 2019-03-21 | Verano Ilac Sanayi Ve Ticaret Anonim Sirketi | VETERINARY COMPOSITION TO BE POURED COMPRISING EPRINOMECTIN |
GB201715122D0 (en) * | 2017-09-19 | 2017-11-01 | Omnipharm Dev Ltd | Topical anti-infective formulation |
CA3114704A1 (en) * | 2018-10-12 | 2020-04-16 | Hovione Scientia | Macrocyclic lactone formulations, methods of their preparation and use of the formulations in treating pathologies secondary to ophthalmic parasites |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013508A1 (fr) * | 1995-10-13 | 1997-04-17 | Virbac S.A. | Composition liquide a usage topique, son procede de preparation et ses applications |
US20020010142A1 (en) * | 2000-02-16 | 2002-01-24 | Richard Mihalik | Parasiticidal formulation and a method of making this formulation |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2731386A (en) * | 1951-09-06 | 1956-01-17 | Wallace & Tiernan Company Inc | Antifungal composition |
US3798258A (en) * | 1970-03-13 | 1974-03-19 | Merck & Co Inc | Salicylanilides |
LU62350A1 (ja) * | 1970-12-31 | 1972-08-23 | ||
US3950360A (en) | 1972-06-08 | 1976-04-13 | Sankyo Company Limited | Antibiotic substances |
US4005218A (en) | 1975-03-18 | 1977-01-25 | Janssen Pharmaceutica N.V. | Antiparasitic salicylanilide derivatives |
SE434277B (sv) | 1976-04-19 | 1984-07-16 | Merck & Co Inc | Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis |
US4206205A (en) | 1977-10-03 | 1980-06-03 | Merck & Co., Inc. | Monosaccharide and aglycone derivatives of C-076 |
US4199569A (en) | 1977-10-03 | 1980-04-22 | Merck & Co., Inc. | Selective hydrogenation products of C-076 compounds and derivatives thereof |
US4201861A (en) | 1977-10-03 | 1980-05-06 | Merck & Co., Inc. | Acyl derivatives of C-076 compounds |
US4173571A (en) | 1977-12-19 | 1979-11-06 | Merck & Co., Inc. | 13-Halo and 13-deoxy derivatives of C-076 compounds |
US4171314A (en) | 1977-12-19 | 1979-10-16 | Merck & Co., Inc. | 13-Halo and 13-deoxy C-076 compounds |
OA06863A (fr) | 1980-08-04 | 1983-02-28 | Merck & Co Inc | Solubilisation de l'invermectine dans l'eau. |
NZ210505A (en) | 1983-12-22 | 1988-06-30 | Merck & Co Inc | Parasiticidal compositions containing avermectin or milbemycin derivatives |
NZ335166A (en) | 1999-04-14 | 2001-11-30 | Ashmont Holdings Ltd | Anthelmintic composition containing triclabendazole in at least one solvent |
RU2033150C1 (ru) | 1992-06-10 | 1995-04-20 | Виктор Антонович Дриняев | Препарат для лечения и профилактики псороптоза у животных "аверсект" |
PL174488B1 (pl) * | 1993-05-10 | 1998-08-31 | Merck & Co Inc | Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt |
ES2170099T3 (es) * | 1993-05-26 | 2002-08-01 | Commw Scient Ind Res Org | Composiciones antiparasitarias. |
EP0710105B1 (en) | 1993-06-15 | 2003-07-30 | The Australian National University | Synergistic anthelmintic compositions against fasciola hepatica and other fasciola species |
NZ248486A (en) | 1993-08-24 | 1996-07-26 | Ashmont Holdings Limited Subst | Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent |
RU2112508C1 (ru) | 1995-12-26 | 1998-06-10 | Писков Вячеслав Борисович | Способ лечения и профилактики саркоптоидозов животных |
RU2121831C1 (ru) | 1997-08-01 | 1998-11-20 | Анатолий Александрович Непоклонов | Препарат для профилактики и лечения гиподерматоза крупного рогатого скота |
AUPP105497A0 (en) * | 1997-12-19 | 1998-01-15 | Schering-Plough Animal Health Limited | Aqueous insecticidal pour-on treatment |
RU2129430C1 (ru) | 1998-03-17 | 1999-04-27 | Общество С Ограниченной Ответственностью "Вик - Здоровье Животных" | Препарат для борьбы с экто- и эндопаразитами животных "сантомектин" |
US6239119B1 (en) * | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
GB9816132D0 (en) * | 1998-07-24 | 1998-09-23 | Norbrook Lab Ltd | Non-aqueous anthelmintic composition |
GEP20012490B (en) | 1999-10-21 | 2001-07-25 | Robizon Bostashvili | Means Against Demodicosis of Agricultural and Domestic Animals |
US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
AUPQ875700A0 (en) * | 2000-07-13 | 2000-08-03 | Reflex Research Limited | Combination compositions |
CA2449103A1 (en) * | 2001-06-01 | 2002-12-12 | Tendskin Company | Topical compositions for veterinary uses |
GB2386067A (en) * | 2002-02-28 | 2003-09-10 | Norbrook Lab Ltd | Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species |
AU2003275779B2 (en) * | 2002-11-11 | 2009-02-05 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
AU2002952597A0 (en) * | 2002-11-11 | 2002-11-28 | Schering-Plough Pty. Limited | Topical parasiticide formulations and methods of treatment |
AU2003900505A0 (en) * | 2003-02-05 | 2003-02-20 | Jurox Pty Ltd | Anthelmintic composition |
-
2003
- 2003-07-12 GB GBGB0316377.1A patent/GB0316377D0/en not_active Ceased
-
2004
- 2004-07-12 OA OA1200600008A patent/OA13188A/en unknown
- 2004-07-12 KR KR1020067000779A patent/KR101095419B1/ko not_active IP Right Cessation
- 2004-07-12 SI SI200431947T patent/SI1646425T1/sl unknown
- 2004-07-12 CN CN200480020006XA patent/CN1822880B/zh not_active Expired - Fee Related
- 2004-07-12 AU AU2004257450A patent/AU2004257450B2/en active Active
- 2004-07-12 EP EP04743347A patent/EP1646425B1/en active Active
- 2004-07-12 GB GB0415541A patent/GB2403905B/en active Active
- 2004-07-12 MX MXPA06000135A patent/MXPA06000135A/es active IP Right Grant
- 2004-07-12 PL PL04743347T patent/PL1646425T3/pl unknown
- 2004-07-12 EP EP10012261A patent/EP2286876A1/en not_active Withdrawn
- 2004-07-12 NZ NZ544973A patent/NZ544973A/en unknown
- 2004-07-12 ES ES04743347T patent/ES2390224T3/es active Active
- 2004-07-12 WO PCT/GB2004/003006 patent/WO2005007241A1/en active Application Filing
- 2004-07-12 BR BRPI0412522-3A patent/BRPI0412522A/pt not_active IP Right Cessation
- 2004-07-12 DK DK04743347.9T patent/DK1646425T3/da active
- 2004-07-12 AP AP2006003506A patent/AP2956A/xx active
- 2004-07-12 GE GEAP20049216A patent/GEP20094648B/en unknown
- 2004-07-12 EA EA200600237A patent/EA009602B1/ru not_active IP Right Cessation
- 2004-07-12 CA CA2532199A patent/CA2532199C/en not_active Expired - Fee Related
- 2004-07-12 JP JP2006519991A patent/JP4677405B2/ja active Active
- 2004-07-12 PT PT04743347T patent/PT1646425E/pt unknown
-
2006
- 2006-01-05 CR CR8174A patent/CR8174A/es unknown
- 2006-01-09 TN TNP2006000006A patent/TNSN06006A1/en unknown
- 2006-01-10 IL IL173057A patent/IL173057A/en not_active IP Right Cessation
- 2006-01-12 US US11/330,671 patent/US8993546B2/en active Active
- 2006-01-13 ZA ZA200600374A patent/ZA200600374B/en unknown
- 2006-02-10 NO NO20060676A patent/NO336181B1/no not_active IP Right Cessation
- 2006-02-10 EC EC2006006360A patent/ECSP066360A/es unknown
-
2007
- 2007-02-09 HK HK07101577.2A patent/HK1096621A1/xx not_active IP Right Cessation
-
2012
- 2012-09-10 HR HRP20120721TT patent/HRP20120721T1/hr unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997013508A1 (fr) * | 1995-10-13 | 1997-04-17 | Virbac S.A. | Composition liquide a usage topique, son procede de preparation et ses applications |
US20020010142A1 (en) * | 2000-02-16 | 2002-01-24 | Richard Mihalik | Parasiticidal formulation and a method of making this formulation |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4480400B2 (ja) | サリチルアニリド化合物、ポリマー成分および少なくとも1種の他の抗寄生虫化合物を含む持続性駆虫組成物 | |
EP1887866B1 (en) | Spot-on formulations for combating parasites | |
EP1130966B1 (en) | Antiparasitic formulations | |
US8993546B2 (en) | Parasiticidal composition | |
AU2008282388A1 (en) | Endoparasiticidal topical compositions | |
AU2006322120A1 (en) | Benzimidazole non-aqueous compositions | |
GB2386067A (en) | Long-acting parasiticidal composition with improved bioavailability comprising an avermectin or milbemycin, plus a salicylanilide & a polymeric species | |
CN111386112A (zh) | 用于治疗寄生虫感染的含有莫昔克丁的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110118 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110131 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140204 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4677405 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |